-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A phase I clinical trial of a monoclonal antibody (mAb) for the treatment of Middle East Respiratory Syndrome (MERS) coronavirus found that the monoclonal antibodies REGN3048 and REGN3051 are well tolerated and safe.
This study is the first human trial.
In preclinical studies, researchers administered REGN3048 and REGN3051 to genetically modified mice (unlike wild-type mice, genetically modified mice can be infected with MERS CoV).
Infection When administered the day before coronavirus exposure, both REGN3048 and REGN3051 can reduce the level of virus detected in the lungs.
prevention
Original source:
Original source:https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here